ML228

ML228 is a small molecule triazine-based research compound that acts as a potent activator of the Hypoxia Inducible Factor (HIF) pathway. Developed through the NIH Molecular Libraries Program, it functions as an iron chelator to stabilize HIF-1α and promote its nuclear translocation, subsequently inducing the expression of downstream genes such as vascular endothelial growth factor (VEGF). Unlike some other HIF activators, ML228 does not inhibit the proteasome. It has been investigated in preclinical models for therapeutic potential in conditions involving hypoxia and ischemia, such as spinal cord injury and muscle regeneration, though it currently remains a research tool and is not approved for clinical use.